184 related articles for article (PubMed ID: 25429050)
1. Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.
Kortüm B; Campregher C; Lang M; Khare V; Pinter M; Evstatiev R; Schmid G; Mittlböck M; Scharl T; Kucherlapati MH; Edelmann W; Gasche C
Gut; 2015 Dec; 64(12):1905-12. PubMed ID: 25429050
[TBL] [Abstract][Full Text] [Related]
2. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
Kucherlapati MH; Lee K; Nguyen AA; Clark AB; Hou H; Rosulek A; Li H; Yang K; Fan K; Lipkin M; Bronson RT; Jelicks L; Kunkel TA; Kucherlapati R; Edelmann W
Gastroenterology; 2010 Mar; 138(3):993-1002.e1. PubMed ID: 19931261
[TBL] [Abstract][Full Text] [Related]
3. Mesalazine improves replication fidelity in cultured colorectal cells.
Gasche C; Goel A; Natarajan L; Boland CR
Cancer Res; 2005 May; 65(10):3993-7. PubMed ID: 15899787
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
[TBL] [Abstract][Full Text] [Related]
5. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors.
Woerner SM; Tosti E; Yuan YP; Kloor M; Bork P; Edelmann W; Gebert J
Mol Carcinog; 2015 Nov; 54(11):1376-86. PubMed ID: 25213383
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
[TBL] [Abstract][Full Text] [Related]
8. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.
Bommi PV; Bowen CM; Reyes-Uribe L; Wu W; Katayama H; Rocha P; Parra ER; Francisco-Cruz A; Ozcan Z; Tosti E; Willis JA; Wu H; Taggart MW; Burks JK; Lynch PM; Edelmann W; Scheet PA; Wistuba II; Sinha KM; Hanash SM; Vilar E
Cancer Res; 2021 May; 81(10):2760-2773. PubMed ID: 34003775
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
10. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
[TBL] [Abstract][Full Text] [Related]
12. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair-deficient crypt foci in Lynch syndrome--molecular alterations and association with clinical parameters.
Staffa L; Echterdiek F; Nelius N; Benner A; Werft W; Lahrmann B; Grabe N; Schneider M; Tariverdian M; von Knebel Doeberitz M; Bläker H; Kloor M
PLoS One; 2015; 10(3):e0121980. PubMed ID: 25816162
[TBL] [Abstract][Full Text] [Related]
14. Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats.
Campregher C; Honeder C; Chung H; Carethers JM; Gasche C
Clin Cancer Res; 2010 Mar; 16(6):1950-6. PubMed ID: 20197483
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite Instability in Mouse Models of Colorectal Cancer.
Currey N; Daniel JJ; Mladenova DN; Dahlstrom JE; Kohonen-Corish MRJ
Can J Gastroenterol Hepatol; 2018; 2018():6152928. PubMed ID: 29686976
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
18. Approach to Lynch Syndrome for the Gastroenterologist.
Bui QM; Lin D; Ho W
Dig Dis Sci; 2017 Feb; 62(2):299-304. PubMed ID: 27990589
[TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemical expression and microsatellite instability in Lynch syndrome].
Vaccaro CA; Carrozzo JE; Mocetti E; Berho M; Valdemoros P; Mullen E; Oviedo M; Redal MA
Medicina (B Aires); 2007; 67(3):274-8. PubMed ID: 17628916
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
